孙祖俊 副主任技师/副教授
硕士招生类型：学术型；专业型
硕士招生专业：临床检验诊断学
博士招生类型：学术型；专业型
博士招生专业：临床检验诊断学
所在院系：附属同济医院
联系方式：sunzujun@tongji.edu.cn
课题组链接：
研究方向
主要任职
科研业绩

肿瘤发病机制、生物标志物筛查及免疫治疗的基础和临床研究 The basic and clinical research of tumor pathogenesis, biomarker screening and immunotherapy
同济大学附属同济医院检验科分子遗传组学科带头人Academic leader of Molecular Genetics, Department of Clinical Laboratory, Tongji Hospital of Tongji University；
上海市医学会检验医学专科分会青年委员Youth Committee, Shanghai Medicine Association of Laboratory Medicine；
白求恩精神研究会检验医学分会青年委员会副主任委员Youth Deputy Director Committee, Bethune Spirit Association of Laboratory Medicine；
上海市中西医结合学会医学检验专业委员会青年委员Youth Committee, Shanghai Chinese and Western Medicine Association of Laboratory Medicine；
白求恩精神研究会区域检验专委会委员Committee, Bethune Spirit Association of Regional Laboratory Medicine；
《国际检验医学》、《检验医学与临床》、《Clinica Chimica Acta》杂志审稿专家The Reviewer of International Journal of Laboratory Medicine, Laboratory Medicine and Clinical, Clinica Chimica Acta；
上海市政府采购评审专家Evaluation Expert of Shanghai Municipal Government Procurement
立项课题：第一负责人主持课题：
1.2020.1-2023.12 国家自然基金面上项目(**) ，55万元；
2.2019.6-2022.5 上海市同济医院临床研究培育重点项目[ITJ(ZD)1905]，25万元；
3.2019.5-2022.4 上海市自然科学基金(19ZR**)， 20万元；
4.2019.4-2022.3 上海市科委医学引导类项目(**)， 20万元；
5.2018.10-2019.9 上海市同济医院国家自然科学基金培育项目(GJPY1804) ，5万元；
6.2018.1-2020.12 上海市科委智慧即时检测示范应用研究(17DZ**) ，3万元；
7.2011.1-2013.12 国家自然科学基金青年项目(**)，20 万元；
8.2010.10-2012.9 上海交通大学附属第九人民医院院级课题， 2 万元
发表SCI论文：第一/通讯作者：
1.Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis. Mol Cancer, 2020, 19:117-31；
2.Long Non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression. Aging (Albany NY). 2020, 12(9): 8301-8320；
3.Exosomal miR-183-5p Promotes Angiogenesis in Colorectal Cancer by Regulation of FOXO1. Aging (Albany NY). 2020, 12(9): 8352-8371；
4.Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration. Cell Commun Signal. 2020, 18(1):52；
5.Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. Journal of Experimental & Clinical Cancer Research. 2019, 38:1-15；
6.Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling. Theranostics. 2019, 9(8):2209-23；
7.Bronchoalveolar lavage fluid-derived exosomes: a novel role contributing to lung cancer growth. Frontiers in Oncology. 2019,197:1-11；
8.A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. Ivest New Drug. 2018, 26(6):1-12；
9.A deficiency in cathelicidin reduces lung tumor growth in NNK/NTHi-induced A/J mice. Am J Cancer Res. 2018, 8:1190-9；
10.The value of red blood cell distribution width in diagnosis of patients with colorectal cancer. Clinica Chimica Acta. 2018, 479: 98-102；
11.Role of c-Met in the progression of human oral squamous cell carcinoma and its potential as a therapeutic target. Oncol Rep. 2018, 39: 209-216；
12.A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. Oncotarget. 2017, 8: 29067-79；
13.Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation. Oncol Rep. 2013, 29:1701-6；
14.Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis. Mol Cancer. 2012. 11:1-12